TRAPANI, DARIO
TRAPANI, DARIO
Dipartimento di Oncologia ed Emato-Oncologia
Extendeond Endocrine Therapy and Survival for Breast Cancer Subtypes in Premenopausal Patients
2026 C. Valenza, Y. Zheng, M. Milano, P.P.M. Berton Giachetti, D. Trapani, E. Giordano, L. Guidi, L. Boldrini, G. Castellano, J. Katrini, B. Malagutti, G. Antonarelli, J.D. Etessami, N. Bianco, F. Conforti, G.J. Kirkner, C. Sangalli, K.E. Dibble, N. Fusco, M. Colleoni, M.M. Regan, E. Munzone, G. Curigliano, A.H. Partridge
Invasive lobular and ductal breast cancers: a systematic review and metanalysis in association with BRCA1/2 mutation status
2026 G. Corso, C. Andreon, C. La Vecchia, E.I. Bottazzoli, G. Abruzzese, K. Favilla, O. Citterio, E. Spoldi, S. Di Silvestre, A.M. De Scalzi, A. Polizzi, E. Meduri, D. Trapani, L. Nicosia, F. Pesapane, D. Bossi, E. Brogi, S. Shen, R. Mukhtar, C. Criscitiello, P. Veronesi, S. Gandini, F. Magnoni, G. Curigliano
Do all patients with early breast cancer meeting the NATALEE criteria benefit from adjuvant ribociclib?
2025 C. Valenza, D. Trapani, G. Curigliano
Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment
2025 B. Taurelli Salimbeni, F. Giudici, C. Pescia, P.P.M. Berton Giachetti, R. Scafetta, P. Zagami, A. Marra, D. Trapani, A. Esposito, S. Scagnoli, B. Cerbelli, A. Botticelli, E. Munzone, N. Fusco, C. Criscitiello, G. Curigliano
An update on promising and emerging protein kinase B/AKT inhibitors for breast cancer
2025 R. Asnaghi, G. Antonarelli, E. Battaiotto, G. Castellano, L. Guidi, D. Izzo, P. Zagami, D. Trapani, G. Curigliano
Mismatch repair (MMR) and microsatellite instability (MSI) phenotypes across solid tumors: A comprehensive cBioPortal study on prevalence and prognostic impact
2025 K. Venetis, C. Frascarelli, L.B. Bielo, G. Cursano, R. Adorisio, M. Ivanova, E. Mane, V. Peruzzo, A. Concardi, M. Negrelli, M. D'Ercole, F.M. Porta, Y. Zhan, A. Marra, D. Trapani, C. Criscitiello, G. Curigliano, E. Guerini-Rocco, N. Fusco
The pathologic and genomic evolution of primary malignant phyllodes tumors of the breast: retrospective cohort study and case-control genomic analysis
2025 C. Valenza, D. Trapani, F.M. Porta, E. Olmeda, A. Gaeta, L. Boscolo Bielo, F. Conversano, T.M. De Pas, G. Castellano, C. Santoro, E. Battaiotto, E. Mane, S. Coppola, F. Conforti, D. Mattar, S. Gandini, P. Veronesi, E. Guerini Rocco, E. Pennacchioli, G. Curigliano
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
2025 P.P.M. Berton Giachetti, S. Morganti, S. Gandini, F. Giudici, A. Marra, E. Nicolò, E. Zattarin, C. Corti, L. Boldrini, A. Verrazzo, C. Sposetti, M.G. Razeti, A. Carnevale Schianca, R. Scafetta, B. Taurelli Salimbeni, A. Esposito, P. Zagami, D. Trapani, B. Malagutti, R. Caputo, C. Vernieri, E. Munzone, S. Scagnoli, A. Botticelli, M. Lambertini, M. Giuliano, M. De Laurentiis, G. Viale, G. Bianchini, G. Curigliano, C. De Angelis, C. Criscitiello
Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy
2025 D. Izzo, L. Ascione, L. Guidi, R.M. Marsicano, C. Koukoutzeli, D. Trapani, G. Curigliano
Breast surgery and systemic treatment continuation for patients with de novo metastatic breast cancer and locoregional oligoprogression: a cohort study
2025 C. Valenza, N. Bianco, M. Milano, D. Trapani, S. Di Bella, A. Sciandivasci, I. Minchella, C. Sangalli, V. Galimberti, M. Intra, P. Veronesi, E. Munzone, M. Colleoni, G. Curigliano
Molecular tumor board in patients with metastatic breast cancer
2025 L. Boscolo Bielo, E. Guerini Rocco, E. Crimini, M. Repetto, M. Lombardi, C. Zanzottera, G. Aurilio, M. Barberis, C. Belli, Y. Zhan, E. Battaiotto, J. Katrini, R. Marsicano, P. Zagami, B. Taurelli Salimbeni, A. Esposito, D. Trapani, C. Criscitiello, N. Fusco, A. Marra, G. Curigliano
Radioligand Therapy in Metastatic Breast Cancer: Harnessing Precision Oncology
2025 F. Giugliano, E. Giordano, L. Gilardi, B.T. Salimbeni, P. Zagami, A. Esposito, A. Marra, D. Trapani, P.P.M. Berton Giachetti, B. Malagutti, T. Henry, D. Deandreis, G. Curigliano, F. Ceci, C. Criscitiello
ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0)
2025 N.I. Cherny, S.F. Oosting, U. Dafni, N.J. Latino, M. Galotti, P. Zygoura, G. Dimopoulou, T. Amaral, J. Barriuso, A. Calles, B. Kiesewetter, C. Gomez-Roca, B. Gyawali, M. Piccart, A. Passaro, F. Roitberg, N. Tarazona, D. Trapani, G. Curigliano, R. Wester, G. Zarkavelis, C. Zielinski, E.G.E. De Vries
Sacituzumab govitecan in the first-line treatment of triple-negative breast cancer: balancing therapeutic sequencing with patient-relevant benefits
2025 D. Trapani, C. Valenza, G. Curigliano
Next-generation sequencing methodologies to identify patients for targeted therapy: focus on HR+/HER2- metastatic breast cancer
2025 U. Malapelle, S. Buglioni, I. Castellano, C. Criscitiello, G. Curigliano, G. D'Amati, C. De Angelis, D. De Biase, F. Pepe, G. Perrone, C. Scatena, M. Scatolini, D. Trapani, K. Venetis, N. Fusco
Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer
2025 M. Milano, C. Valenza, A. Ferrari, S. Gandini, D. Trapani, C. Santoro, E. Battaiotto, A. Carnevale Schianca, E. Giordano, J. Katrini, G. Castellano, B. Taurelli Salimbeni, M.C. Leonardi, S. Dicuonzo, C. Criscitiello, N. Bianco, S. Dellapasqua, E. Munzone, G. Curigliano, M. Colleoni, B.A. Jereczek-Fossa
Germline BRCA pathogenic variants and hematologic adverse events in patients with ovarian carcinoma receiving PARP inhibitors: a retrospective cohort study
2025 C. Valenza, E. Nicolò, M. Mongillo, D. Trapani, J. Katrini, L. Boldrini, L. Boscolo Bielo, G. Castellano, L. Guidi, G. Pellizzari, J. Villa, S. Derio, M. Lapresa, F. Gigli, G. Parma, E. Omodeo Salè, E. Derenzini, G. Curigliano, N. Colombo
Targeting androgen receptors in patients with metastatic breast cancer
2025 L. Guidi, D. Trapani, G. Curigliano
Monitoring serum estradiol in premenopausal women with hormone receptor-positive breast cancer on adjuvant LHRH agonists
2025 C. Valenza, J.D. Etessami, E. Munzone, G. Pravettoni, G. Curigliano, D. Trapani
Real-world safety and efficacy profiles of trastuzumab deruxtecan in patients with advanced breast cancer
2025 G. Antonarelli, M. Milano, C. Andreon, S. Gandini, G. Pellizzari, D. Trapani, S. Dellapasqua, A. Marra, P. Zagami, C. Valenza, M. Colleoni, E. Munzone, G. Curigliano